ZYBERNO
Stock Report
Updated Sep 1, 2026

CANDEL THERAPEUTICS, INC. (CADL)

Healthcare • NASDAQ

$13.07

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
12.0/100
POOR BUSINESS
CANDEL THERAPEUTICS, INC. (CADL) scores 12/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-89.4%)
Debt-to-Equity (Solvency Risk):GOOD (0.38x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-820.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

CANDEL THERAPEUTICS, INC. (CADL) stock report — Zyberno Score 12/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, CADL generated -$48.26M in Owner Earnings. Capital was deployed as follows: $1.26M invested in capital expenditures. Reinvestment rate: 0.5%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:13.07
Market Cap:$968.90M

Valuation Multiples (2)

P/B Ratio:7.68x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$793.16M

Price Action & Momentum (3)

Momentum Percentile:92 / 100
% of 52-Week High:93.4%
B. Profitability Assessment

Return Metrics (5)

ROA:-56.3%
Reinvestment Rate:0.5%
Fundamental Growth Rate (g):-3.9%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$10.86
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-2,375.0%
Latest Earnings Filed:2026-08-13
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:16.09x
Quick Ratio:16.09x
Cash Ratio:15.89x

Leverage Analysis (3)

Debt To Equity Ttm:0.38x
Debt-to-Equity Ratio:0.38x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-10.23x
Times Interest Earned:-10.23

Capital Structure (4)

Working Capital:191,473,000.00
Cash And Cash Equivalents:201,565,000.00
Long Term Debt:$22.02M
Net Debt:-$175.74M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$71.99M

Bottom Line Performance (3)

-$88.53M
Income Before Tax:-$38.18M
Ebitda Ttm:-71,240,000.00

Operating Expenses (5)

Operating Expenses:71,989,000.00
R And D Expense:49,130,000.00
Sga Expense:22,859,000.00
Income Tax Expense:$0.00
Interest Expense:4,716,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$208.15M
Current Assets:$204.16M
Ppe Net:2,002,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:82,019,000.00
Current Liabilities:12,685,000.00
Long Term Debt:$22.02M
Short Term Debt:$3.81M

Equity & Capital (3)

Equity:$126.13M
Retained Earnings:-$278.15M
Common Stock:150,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:5,154,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:2,858,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$47.73M-$48.99M

Investment Activities (2)

Investing Cash Flow:-$675.00K
Capital Expenditures Ttm:1,259,000.00

Financing Activities (3)

Financing Cash Flow:$93.82M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:384,000.00
Long Term Debt Issuance:$47.95M
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:749,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.44
-$1.42
Earnings Per Share Ttm:-$1.19

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.52

Book Value & Capital (2)

Book Value Per Share:$1.70
Cash Per Share:2.72

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$48.26M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.5%
Fundamental Growth Rate (g):-3.9%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):24.9%
C. Company Profile & Context

Corporate Information (6)

Symbol:CADL
Company Name:CANDEL THERAPEUTICS, INC.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:74.13M
Shares Outstanding Basic:74.13M
Shares Outstanding Diluted:74.13M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 16:50:39 UTC
Data Timestamp:2026-09-01T16:50:39.265462
Scroll to Top